Tim Smith

During this interview segment, Dr. Yosipovitch discussed his overview of current PN research and a specific study he had presented at EADV.

This discussion with Dr. Yosipovitch covered findings presented at EADV 2023 on dupilumab and prurigo nodularis patients’ satisfaction.

This data from the NOTUS trial is set to be submitted to the FDA alongside the phase 3 BOREAS trial data later in the year.

During this interview segment, Dr. Chovatiya further analyzed the updated National Psoriasis Foundation consensus statements for GPP and the future of treatment research.

These pivotal trial results from a study in China indicated the potential of this drug as a quarterly treatment for individuals with eczema.

This phase 3 program was advised to discontinue given that cobitolimod was shown to be less likely to meet its primary endpoint.

In this interview, Dr. Chovatiya summarized and discussed the updated National Psoriasis Foundation consensus statements for GPP.

This research provides an early analysis of plaque psoriasis patients within routine clinical practice settings and outside of a clinical trial setting.

This news from the FDA followed a resubmission after the FDA’s complete response letter for the P2X3 receptor antagonist’s use in refractory chronic cough and unexplained cough.

This long-term data on dupilumab investigated both survival rates and rationale for treatment discontinuation.

During this segment of his interview, Dr. Kim went into the Harmony study data on safety of ADP101 presented at ACAAI as well as the implications of the research.

In this interview segment, Dr. Kim described some of the background and importance of the Harmony study data presented at ACAAI for patients with food allergy.

This new data may help health policymakers to better strategize their approaches to management of childrens’ nutritional anemias.

This new data showed that spreading awareness about pneumococcal infection and prophylaxis could help to improve health outcomes and reduce mortality related to infections in those with SCD.

The study’s investigators suggest the results in this patient population may indicate rises in clinically diagnosed viral infections from viruses other than SARS-CoV-2 following pandemic lockdown changes.

This new research looked at a nationwide birth cohort of mother–child pairs in Japan, allowing for a wide array of data on this less well-studied topic.

This is the first research to allow for greater insight into the impacts on providers of a nationwide change to an adalimumab biosimilar.

This study provides further support for the efficacy of this biosimilar, allowing for potential future reduction in costs for patients with IBD.

This new research opens the door for further biological agent use in IBD therapy, helping to expand patients’ array of options when seeking IBD treatment in different countries.

This new data indicates both the high mental health burden on this patient population as well as the usefulness of integrated behavioral health care teams in clinics with a pediatric specialty.

This research highlights the close relationship between pollen-induced allergic rhinitis, sensitization, and asthma.

This new data suggests that hospital facilities in the US may need to plan for potentially atypical timing of bronchiolitis season once more for 2023.

In this segment of his interview, Dr. Chovatiya discussed some of the key safety data on secukinumab following the drug’s FDA approval for hidradenitis suppurativa.

In this interview, Dr. Chovatiya responds to questions about the new FDA approval of secukinumab for patients with hidradenitis suppurativa.

This new research sheds light on the importance of follow-up meetings for young patients discharged from emergency departments.

This segment of Dr. Kwatra’s latest interview featured a discussion on the future of prurigo nodularis treatment and the implications of his team’s research.

In this interview, Dr. Kwatra explored the recent phase 3 data from the Olympia 2 study on nemolizumab treatment for patients with prurigo nodularis.

These new results highlight the importance of further examining the link between cyberbullying, social pressures, academic performance, and eczema.

This new data highlights the value of proper counseling regarding possible adverse effects prior to initiation of treatment initiation with JAK inhibitors.

This interview with Dr. Feldman involved a discussion on new findings regarding atopic dermatitis patient preferences and racial disparities in dermatologic care.